Effects of the combined blockade of EGFR and ErbB-2 on signal transduction and regulation of cell cycle regulatory proteins in breast cancer cells

Breast Cancer Research and Treatment

Volumn 123, Issue 2, 2010, Pages 387-396

  D'Alessio, Amelia ^a   De Luca, Antonella ^a   Maiello, Monica R ^a   Lamura, Luana ^a   Rachiglio, Anna Maria ^b   Napolitano, Maria ^a   Gallo, Marianna ^a   Normanno, Nicola ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b CROM   (Italy)

Author keywords

Breast cancer; Cell cycle; EGFR; ErbB 2

Indexed keywords

CYCLIN D1; CYCLIN DEPENDENT KINASE INHIBITOR 1B; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; GEFITINIB; LAPATINIB; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; PROTEIN P130; SURVIVIN; TRANSCRIPTION FACTOR FKHRL1; TRASTUZUMAB;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL CYCLE REGULATION; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DRUG POTENTIATION; ENZYME ACTIVATION; ENZYME INHIBITION; HUMAN; HUMAN CELL; MONOTHERAPY; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TRANSCRIPTION REGULATION;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CELL CYCLE; CELL CYCLE PROTEINS; CELL LINE, TUMOR; DRUG SYNERGISM; FEMALE; FORKHEAD TRANSCRIPTION FACTORS; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MITOGEN-ACTIVATED PROTEIN KINASES; PHOSPHORYLATION; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-AKT; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; RETINOBLASTOMA-LIKE PROTEIN P130; RNA INTERFERENCE; RNA, MESSENGER; SIGNAL TRANSDUCTION; TIME FACTORS;

EID: 77956182872     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-009-0649-x     Document Type: Article

References (46)

1. Y Kokai JN Myers T Wada VI Brown CM LeVea JG Davis K Dobashi MI Greene 1989 Synergistic interaction of p185c-neu and the EGF receptor leads to transformation of rodent fibroblasts Cell 58 287 292 10.1016/0092-8674(89)90843- X 2568888
2. MP DiGiovanna MA Lerman RJ Coffey WJ Muller RD Cardiff DF Stern 1998 Active signaling by Neu in transgenic mice Oncogene 17 1877 1884 10.1038/sj.onc.1202091 9778054
3. WJ Muller CL Arteaga SK Muthuswamy PM Siegel MA Webster RD Cardiff KS Meise F Li SA Halter RJ Coffey 1996 Synergistic interaction of the Neu proto-oncogene product and transforming growth factor alpha in the mammary epithelium of transgenic mice Mol Cell Biol 16 5726 5736 8816486
4. C Lu C Speers Y Zhang X Xu J Hill E Steinbis J Celestino Q Shen H Kim S Hilsenbeck SK Mohsin A Wakeling CK Osborne PH Brown 2003 Effect of epidermal growth factor receptor inhibitor on development of estrogen receptor-negative mammary tumors J Natl Cancer Inst 95 1825 1833 14679152
5. AL Harris S Nicholson JR Sainsbury J Farndon C Wright 1989 Epidermal growth factor receptors in breast cancer: association with early relapse and death, poor response to hormones and interactions with neu J Steroid Biochem 34 123 131 10.1016/0022-4731(89)90072-1 2576295
6. A Osaki M Toi H Yamada H Kawami K Kuroi T Toge 1992 Prognostic significance of co-expression of c-erbB-2 oncoprotein and epidermal growth factor receptor in breast cancer patients Am J Surg 164 323 326 10.1016/S0002-9610(05)80897-9 1357997
7. A Harlozinska JK Bar R Wenderski M Bebenek 1996 Relationship between c-erbB-2 oncoprotein, epidermal growth factor receptor, and estrogen receptor expression in patients with ductal breast carcinoma. Association with tumor phenotypes In Vivo 10 217 222 8744803
8. MP DiGiovanna DF Stern SM Edgerton SG Whalen D Moore II AD Thor 2005 Relationship of epidermal growth factor receptor expression to ErbB-2 signaling activity and prognosis in breast cancer patients J Clin Oncol 23 1152 1160 10.1200/JCO.2005.09.055 15718311
9. SM Wiseman N Makretsov TO Nielsen B Gilks E Yorida M Cheang D Turbin K Gelmon DG Huntsman 2005 Coexpression of the type 1 growth factor receptor family members HER-1, HER-2, and HER-3 has a synergistic negative prognostic effect on breast carcinoma survival Cancer 103 1770 1777 10.1002/cncr.20970 15770691
10. J Anido P Matar J Albanell M Guzman F Rojo J Arribas S Averbuch J Baselga 2003 ZD1839, a specific epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, induces the formation of inactive EGFR/HER2 and EGFR/HER3 heterodimers and prevents heregulin signaling in HER2-overexpressing breast cancer cells Clin Cancer Res 9 1274 1283 12684395
11. SL Moulder FM Yakes SK Muthuswamy R Bianco JF Simpson CL Arteaga 2001 Epidermal growth factor receptor (HER1) tyrosine kinase inhibitor ZD1839 (Iressa) inhibits HER2/neu (erbB2)-overexpressing breast cancer cells in vitro and in vivo Cancer Res 61 8887 8895 11751413
12. MM Moasser A Basso SD Averbuch N Rosen 2001 The tyrosine kinase inhibitor ZD1839 ("Iressa") inhibits HER2-driven signaling and suppresses the growth of HER2-overexpressing tumor cells Cancer Res 61 7184 7188 11585753
13. N Normanno M Campiglio A De Luca G Somenzi M Maiello F Ciardiello L Gianni DS Salomon S Menard 2002 Cooperative inhibitory effect of ZD1839 (Iressa) in combination with trastuzumab (Herceptin) on human breast cancer cell growth Ann Oncol 13 65 72 10.1093/annonc/mdf020 11863114
14. M Campiglio A Locatelli C Olgiati N Normanno G Somenzi L Vigano M Fumagalli S Menard L Gianni 2004 Inhibition of proliferation and induction of apoptosis in breast cancer cells by the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor ZD1839 ('Iressa') is independent of EGFR expression level J Cell Physiol 198 259 268 10.1002/jcp.10411 14603528
15. A Agrawal E Gutteridge JM Gee RI Nicholson JF Robertson 2005 Overview of tyrosine kinase inhibitors in clinical breast cancer Endocr Relat Cancer 12 Suppl 1 S135 S144 10.1677/erc.1.01059 16113090
16. A Polychronis HD Sinnett D Hadjiminas H Singhal JL Mansi D Shivapatham S Shousha J Jiang D Peston N Barrett D Vigushin K Morrison E Beresford S Ali MJ Slade RC Coombes 2005 Preoperative gefitinib versus gefitinib and anastrozole in postmenopausal patients with oestrogen-receptor positive and epidermal-growth-factor-receptor-positive primary breast cancer: a double-blind placebo-controlled phase II randomised trial Lancet Oncol 6 383 391 10.1016/S1470-2045(05)70176-5 15925816
17. N Normanno A De Luca MR Maiello M Mancino A D'Antonio M Macaluso F Caponigro A Giordano 2005 Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in breast cancer: current status and future development Front Biosci 10 2611 2617 10.2741/1725 15970523
18. KS Albain R Elledge WJ Gradishar DF Hayes E Rowinsky C Hudis L Pusztai D Tripathy S Modi S Rubi 2002 Open-label, phase II, multicenter trial of ZD1839 ('Iressa') in patients with advanced breast cancer Breast Cancer Res Treat 76 S33
19. J Baselga J Albanell A Ruiz A Lluch P Gascon V Guillem S Gonzalez S Sauleda I Marimon JM Tabernero MT Koehler F Rojo 2005 Phase II and tumor pharmacodynamic study of gefitinib in patients with advanced breast cancer J Clin Oncol 23 5323 5333 10.1200/JCO.2005.08.326 15939921
20. NV Sergina M Rausch D Wang J Blair B Hann KM Shokat MM Moasser 2007 Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3 Nature 445 437 441 10.1038/nature05474 17206155
21. N Normanno A Morabito A De Luca MC Piccirillo M Gallo M Maiello F Perrone 2009 Target based therapies in breast cancer: current status and future perspectives Endocr Relat Cancer 16 675 702 10.1677/ERC-08-0208 19525314
22. CL Arteaga A O'Neill SL Moulder M Pins JA Sparano GW Sledge NE Davidson 2008 A phase I-II study of combined blockade of the ErbB receptor network with trastuzumab and gefitinib in patients with HER2 (ErbB2)-overexpressing metastatic breast cancer Clin Cancer Res 14 6277 6283 10.1158/1078-0432.CCR-08- 0482 18829509
23. N Normanno A De Luca MR Maiello C Bianco M Mancino L Strizzi C Arra F Ciardiello S Agrawal DS Salomon 2004 CRIPTO-1: a novel target for therapeutic intervention in human carcinoma Int J Oncol 25 1013 1020 15375551
24. HA Lane I Beuvink AB Motoyama JM Daly RM Neve NE Hynes 2000 ErbB2 potentiates breast tumor proliferation through modulation of p27(Kip1)-Cdk2 complex formation: receptor overexpression does not determine growth dependency Mol Cell Biol 20 3210 3223 10.1128/MCB.20.9.3210-3223.2000 10757805
25. A Brunet A Bonni MJ Zigmond MZ Lin P Juo LS Hu MJ Anderson KC Arden J Blenis ME Greenberg 1999 Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor Cell 96 857 868 10.1016/S0092- 8674(00)80595-4 10102273
26. N Normanno C Bianco A De Luca MR Maiello DS Salomon 2003 Target-based agents against ErbB receptors and their ligands: a novel approach to cancer treatment Endocr Relat Cancer 10 1 21 10.1677/erc.0.0100001 12653668
27. G Valabrega F Montemurro I Sarotto A Petrelli P Rubini C Tacchetti M Aglietta PM Comoglio S Giordano 2005 TGFalpha expression impairs Trastuzumab-induced HER2 downregulation Oncogene 24 3002 3010 10.1038/sj.onc.1208478 15735715
28. SD Pack OM Alper K Stromberg M Augustus M Ozdemirli AM Miermont G Klus M Rusin R Slack NF Hacker T Ried Z Szallasi O Alper 2004 Simultaneous suppression of epidermal growth factor receptor and c-erbB-2 reverses aneuploidy and malignant phenotype of a human ovarian carcinoma cell line Cancer Res 64 789 794 10.1158/0008-5472.CAN-03-1982 14871800
29. H Nakamura S Takamori T Fujii M Ono H Yamana M Kuwano K Shirouzu 2005 Cooperative cell-growth inhibition by combination treatment with ZD1839 (Iressa) and trastuzumab (Herceptin) in non-small-cell lung cancer Cancer Lett 230 33 46 10.1016/j.canlet.2004.12.020 16253759
30. C Larbouret B Robert I Navarro-Teulon S Thezenas MZ Ladjemi S Morisseau E Campigna F Bibeau JP Mach A Pelegrin D Azria 2007 In vivo therapeutic synergism of anti-epidermal growth factor receptor and anti-HER2 monoclonal antibodies against pancreatic carcinomas Clin Cancer Res 13 3356 3362 10.1158/1078-0432. CCR-06-2302 17545543
31. N Normanno A De Luca MR Maiello M Campiglio M Napolitano M Mancino A Carotenuto G Viglietto S Menard 2006 The MEK/MAPK pathway is involved in the resistance of breast cancer cells to the EGFR tyrosine kinase inhibitor gefitinib J Cell Physiol 207 420 427 10.1002/jcp.20588 16419029
32. R Nahta D Yu MC Hung GN Hortobagyi FJ Esteva 2006 Mechanisms of disease: understanding resistance to HER2-targeted therapy in human breast cancer Nat Clin Pract Oncol 3 269 280 10.1038/ncponc0509 16683005
33. E Di Gennaro M Barbarino F Bruzzese S De Lorenzo M Caraglia A Abbruzzese A Avallone P Comella F Caponigro S Pepe A Budillon 2003 Critical role of both p27KIP1 and p21CIP1/WAF1 in the antiproliferative effect of ZD1839 ('Iressa'), an epidermal growth factor receptor tyrosine kinase inhibitor, in head and neck squamous carcinoma cells J Cell Physiol 195 139 150 10.1002/jcp.10239 12599217
34. GC Chang SL Hsu JR Tsai FP Liang SY Lin GT Sheu CY Chen 2004 Molecular mechanisms of ZD1839-induced G1-cell cycle arrest and apoptosis in human lung adenocarcinoma A549 cells Biochem Pharmacol 68 1453 1464 10.1016/j.bcp.2004.06. 006 15345335
35. XF Le FX Claret A Lammayot L Tian D Deshpande R LaPushin AM Tari RC Bast Jr 2003 The role of cyclin-dependent kinase inhibitor p27Kip1 in anti-HER2 antibody-induced G1 cell cycle arrest and tumor growth inhibition J Biol Chem 278 23441 23450 10.1074/jbc.M300848200 12700233
36. MX Sliwkowski JA Lofgren GD Lewis TE Hotaling BM Fendly JA Fox 1999 Nonclinical studies addressing the mechanism of action of trastuzumab (Herceptin) Semin Oncol 26 60 70 10482195
37. FM Yakes W Chinratanalab CA Ritter W King S Seelig CL Arteaga 2002 Herceptin-induced inhibition of phosphatidylinositol-3 kinase and Akt is required for antibody-mediated effects on p27, cyclin D1, and antitumor action Cancer Res 62 4132 4141 12124352
38. LM Tsvetkov KH Yeh SJ Lee H Sun H Zhang 1999 p27(Kip1) ubiquitination and degradation is regulated by the SCF(Skp2) complex through phosphorylated Thr187 in p27 Curr Biol 9 661 664 10.1016/S0960-9822(99)80290-5 10375532
39. RJ Sheaff M Groudine M Gordon JM Roberts BE Clurman 1997 Cyclin E-CDK2 is a regulator of p27Kip1 Genes Dev 11 1464 1478 10.1101/gad.11.11.1464 9192873
40. J Vlach S Hennecke B Amati 1997 Phosphorylation-dependent degradation of the cyclin-dependent kinase inhibitor p27 EMBO J 16 5334 5344 10.1093/emboj/16.17.5334 9311993
41. AC Carrano E Eytan A Hershko M Pagano 1999 SKP2 is required for ubiquitin-mediated degradation of the CDK inhibitor p27 Nat Cell Biol 1 193 199 10.1038/12013 10559916
42. T Hara T Kamura K Nakayama K Oshikawa S Hatakeyama K Nakayama 2001 Degradation of p27(Kip1) at the G(0)-G(1) transition mediated by a Skp2-independent ubiquitination pathway J Biol Chem 276 48937 48943 10.1074/jbc.M107274200 11682478
43. N Nakamura S Ramaswamy F Vazquez S Signoretti M Loda WR Sellers 2000 Forkhead transcription factors are critical effectors of cell death and cell cycle arrest downstream of PTEN Mol Cell Biol 20 8969 8982 10.1128/MCB.20.23. 8969-8982.2000 11073996
44. MF Press RS Finn D Cameron A Di Leo CE Geyer IE Villalobos A Santiago R Guzman A Gasparyan Y Ma K Danenberg AM Martin L Williams C Oliva S Stein R Gagnon M Arbushites MT Koehler 2008 HER-2 gene amplification, HER-2 and epidermal growth factor receptor mRNA and protein expression, and lapatinib efficacy in women with metastatic breast cancer Clin Cancer Res 14 7861 7870 10.1158/1078-0432.CCR-08-1056 19047115
45. CD Britten RS Finn LD Bosserman SG Wong MF Press M Malik BL Lum DJ Slamon 2009 A phase I/II trial of trastuzumab plus erlotinib in metastatic HER2-positive breast cancer: a dual ErbB targeted approach Clin Breast Cancer 9 16 22 10.3816/CBC.2009.n.003 19299235
46. S Khambata-Ford CR Garrett NJ Meropol M Basik CT Harbison S Wu TW Wong X Huang CH Takimoto AK Godwin BR Tan SS Krishnamurthi HA Burris III EA Poplin M Hidalgo J Baselga EA Clark DJ Mauro 2007 Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab J Clin Oncol 25 3230 3237 10.1200/JCO.2006.10.5437 17664471